Zoledronic acid, an aminobisphosphonate, modulates differentiation and maturation of human dendritic cells

Immunopharmacology and Immunotoxicology

Volumn 31, Issue 3, 2009, Pages 499-508

  Chen, Yu Jen ^a,b   Chao, K S Clifford ^c   Yang, Yuh Cheng ^a,d   Hsu, Ming Ling ^a   Lin, Chin Ping ^a   Chen, Yu Yawn ^e  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b CHINESE CULTURE UNIVERSITY   (Taiwan)

^c Howard Hughes Medical Institute   (United States)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY OF SPORT   (Taiwan)

Author keywords

Dendritic cell; Differentiation; Interferon ; Maturation; Zoledronic acid

Indexed keywords

B7 ANTIGEN; CD209 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; GERANYLGERANIOL; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12P70; RAP1 PROTEIN; RAP1A PROTEIN; T6 ANTIGEN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL MATURATION; CELL STIMULATION; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; MONOCYTE; NORMAL HUMAN; OSTEOCLAST; PRENYLATION; PRIORITY JOURNAL; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; ANTIGENS, DIFFERENTIATION; BONE DENSITY CONSERVATION AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; DENDRITIC CELLS; DIPHOSPHONATES; GENE EXPRESSION REGULATION; HUMANS; IMIDAZOLES; IMMUNITY, INNATE; INTERLEUKIN-12; MONOCYTES; PROTEIN PRENYLATION; RAP1 GTP-BINDING PROTEINS;

EID: 70350683571     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923970902814103     Document Type: Article

References (38)

1. Rogers, M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Design. 2003, 32, 2643-2658.
2. Delmas, P.D. Treatment of postmenopausal osteoporosis. Lancet 2002, 359 (9322), 2018-2026.
3. Roux, C., Dougados, M. Treatment of patients with Paget's disease of bone. Drugs 1999, 58 (5), 823-830.
4. Coleman, R.E. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer. Treat. Rev. 2001, 27 (3), 165-176.
5. Rogers, M.J. From molds and macrophages to mevalonate: A decade of progress in understanding the molecular mode of action of bisphosphonates. Calcified. Tissue. Int. 2004, 75 (6), 451-461.
6. Dunford, J.E., Thompson, K., Coxon, F.P., Luckman, S.P., Hahn, F.M., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 2001, 296 (2), 235-242.
7. Amin, D., Cornell, S.A., Gustafson, S.K., Needle, S.J., Ullrich, J.W., et al. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J. Lipid. Res. 1992, 33 (11), 1657-1663.
8. Luckman, S.P., Hughes, D.E., Coxon, F.P., Graham, R., Russell, G., et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 1998, 13 (4), 581-589.
9. Widler, L., Jaeggi, K.A., Glatt, M., Müller, K., Bachmann, R., et al. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J. Med. Chem. 2002, 45 (17), 3721-3738.
10. Durie, B.G., Katz, M., Crowley, J. Osteonecrosis of the jaw and bisphosphonates. New Engl. J. Med. 2005, 353 (1), 99-102.
11. Banchereau, J., Steinman, R.M. Dendritic cells and the control of immunity. Nature 1998, 392 (6673), 245-252.
12. Jonuleit, H., Kuhn, U., Muller, G., Steinbrink, K., Paragnik, L., et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 1997, 27(12), 3135-3142.
13. Kato, T., Yamane, H., Nariuchi, H.. Differential effects of LPS and CD40 ligand stimulations on the induction of IL-12 production by dendritic cells and macrophages. Cell Immunol. 1997, 181 (1), 59-67.
14. Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lanzavecchia, A., et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 1996, 184 (2), 747-752.
15. Labeur, M.S., Roters, B., Pers, B., Mehling, A., Luger, T.A., et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol. 1999, 162 (1), 168-175.
16. Moreau, M.F., Guillet, C., Massin, P., Chevalier, S., Gascan, H., et al. Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. Biochem. Pharmacol. 2007, 73 (5), 718-723.
17. Dieli, F., Gebbia, N., Poccia, F., Caccamo, N., Montesano, C.,et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003, 102 (6), 2310-2311.
18. Fiore, F., Castella, B., Nuschak, B., Bertieri, R., Mariani, S., et al. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood 2007, 110 (3), 921-927.
19. Takahara, M., Miyai, M., Tomiyama, M., Mutou, M., Nicol, A.J., et al. Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigenspecific CD8+ T cells via Vgamma9gammadelta T cell activation. J. Leukoc. Biol. 2008, 83(3), 742-754.
20. Pedersen, A.E., Thorn, M., Gad, M., Walter, M.R., Johnsen, H.E., et al. Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination. Scand. J. Immunol. 2005, 61 (2), 147-156.
21. Colic, M., Mojsilovic, S., Pavlovic, B., Vuciæeviæ, D., Majstoroviæ, I., et al. Comparison of two different protocols for the induction of maturation of human dendritic cells in vitro. Vojnosanit. Pregl. 2004, 61 (5), 471-478.
22. Zhang, M., Tang, H., Guo, Z., An, H., Zhu, X., et al. Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat. Immunol. 2004, 5 (11), 1124-1133.
23. Piemonti, L., Monti, P., Allavena, P., Sironi, M., Soldini, L., et al. Glucocorticoids affect human dendritic cell differentiation and maturation. J. Immunol. 1999, 162 (11), 6473-6481.
24. Lee, J.J., Liao, H.F., Yang, Y.C., Liu, C.L., Chen, Y.Y., et al. Platonin modulates differentiation and maturation of human monocytederived dendritic cells. Int. Immunopharmacol. 2006, 6 (2), 287-293.
25. Linsley, P.S., Brady, W., Urnes, M., Grosmaire, L.S., Damle, N.K., et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 1991a, 174 (3), 561-569.
26. Linsley, P.S., Brady, W., Grosmaire, L., Aruffo, A., Damle, N.K., et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 1991b, 173 (3), 721-730.
27. Doyle, A.M., Mullen, A.C., Villarino, A.V., Hutchins, A.S., High, F.A., et al. Induction of cytotoxic T lymphocyte antigen 4 (CTLA-4) restricts clonal expansion of helper T cells. J. Exp. Med. 2001, 194 (7), 893-902.
28. Fallarino, F., Fields, P.E., Gajewski, T.F. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J. Exp. Med. 1998, 188 (1), 205-210.
29. Sansom, D.M., Manzotti, C.N., Zheng, Y. What's the difference between CD80 and CD86? Trends Immunol. 2003, 24 (6), 314-319.
30. Parlato, S., Santini, S.M., Lapenta, C., Di Pucchio, T., Logozzi, M., Giammarioli, A.M., Malorni, W., Fais, S., Belardelli, F. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFNinduced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood. 2001, 15, 98 (10), 3022-3029.
31. Kellinsalmi, M., Monkkonen, H., Monkkonen, J., Leskelä, H.V., Parikka, V., et al. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts. Basic Clin. Pharma. Toxicol. 2005, 97 (6), 382-391.
32. Chen, T., Berenson, J., Vescio, R., Swift, R., Gilchick, A., et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J. Clin. Pharmacol. 2002, 42 (11), 1228-1236.
33. Woo, S.B., Hellstein, J.W., Kalmar, J.R. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann. Intern. Med. 2006, 144 (10), 753-761.
34. Vincenzi, B., Santini, D., Dicuonzo, G., Battistoni, F., Gavasci, M., et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J. Interf. Cytok. Res. 2005, 25 (3), 144-151.
35. Bringmann, A., Schmidt, S.M., Weck, M.M., Brauer, K.M., von Schwarzenberg, K., et al. Zoledronic acid inhibits the function of Toll-like receptor 4 ligand activated monocyte-derived dendritic cells. Leukemia 2007, 21 (4), 732-738.
36. Coxon, F.P., Helfrich, M.H., Van't Hof, R., Sebti, S., Ralston, S.H., et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298. J. Bone. Miner. Res. 2000, 15 (8), 1467-1476.
37. Suri, S., Mönkkönen, J., Taskinen, M., Pesonen, J., Blank, M.A., et al. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: A model of bisphosphonate-induced gastrointestinal toxicity. Bone 2001, 29 (4), 336-343.
38. Coxon, J.P., Oades, G.M., Kirby, R.S., Colston, K.W. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. B.J.U. Int. 2004, 94 (1), 164-170.